Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and...

Area of Science:

• Cardiology
• Mitochondrial Biology
• Pharmacology

Background:

• Heart failure (HF) involves energy deficits, altered calcium handling, and inflammation, all linked to mitochondrial dysfunction.
• Cannabidiol (CBD) has demonstrated potential in preventing mitochondrial dysfunction.
• This suggests CBD could be a therapeutic agent for mitigating HF progression.

Purpose of the Study:

• To investigate the cardioprotective effects of cannabidiol (CBD) in a mouse model of heart failure (HF).
• To determine if CBD can prevent or reverse HF-associated pathologies and preserve cardiac function.

Main Methods:

• Administration of subcutaneous cannabidiol (CBD) to mice with induced heart failure (HF).
• Assessment of cardiac fibrosis, hypertrophy, ejection fraction, and inflammation.
• Evaluation of isolated cardiomyocyte function, including cell shortening, calcium handling, and mitochondrial function.
• Investigation of CBD-mediated mechanisms using hypertrophied ventricular cardiomyoblasts, focusing on peroxisome proliferator-activated gamma receptors.

Main Results:

• CBD treatment attenuated cardiac fibrosis, hypertrophy, and inflammation in HF mice.
• Ejection fraction was preserved in CBD-treated mice.
• Isolated cardiomyocytes from CBD-treated mice showed preserved cell shortening, calcium handling, mitochondrial function, and redox balance.
• Evidence suggests CBD exerts effects via peroxisome proliferator-activated gamma receptors.

Conclusions:

• Cannabidiol (CBD) limits cardiac hypertrophy and preserves contractile function in heart failure (HF).
• CBD sustains cardiomyocyte and mitochondrial function by maintaining redox balance.
• These findings support the role of CBD as a potential cardioprotective therapy for HF.